Orthoclone OKT3 Alternatives Compared
Orthoclone OKT3 (muromonab-cd3) | Myfortic (mycophenolic acid) | Mycophenolic acid |
|
---|
Orthoclone OKT3 (muromonab-cd3) | Myfortic (mycophenolic acid) | Mycophenolic acid |
|
|||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Prescription only
Prescribed for Rejection Prophylaxis, Rejection Reversal. Orthoclone OKT3 may also be used for purposes not listed in this medication guide. |
Prescription only
Prescribed for Dermatomyositis, Rejection Prophylaxis. Myfortic may also be used for purposes not listed in this medication guide. |
Prescription only
Prescribed for Dermatomyositis, Rejection Prophylaxis. Mycophenolic acid may also be used for purposes not listed in this medication guide. |
Related suggestions Rejection Prophylaxis
|
|||||||||||||||
More about Orthoclone OKT3 (muromonab-cd3) | More about Myfortic (mycophenolic acid) | More about Mycophenolic acid | ||||||||||||||||
Ratings & Reviews | ||||||||||||||||||
Be the first to share your experience with this drug. |
Myfortic has an average rating of 8.6 out of 10 from a total of 5 ratings on Drugs.com. 80% of reviewers reported a positive effect, while 0% reported a negative effect. |
Mycophenolic acid has an average rating of 8.7 out of 10 from a total of 9 ratings on Drugs.com. 78% of reviewers reported a positive effect, while 0% reported a negative effect. |
||||||||||||||||
Side Effects Experienced by Users Side effects are reported in Drugs.com user reviews and not clinically verified. | ||||||||||||||||||
View all Orthoclone OKT3 side effects |
View all Myfortic side effects |
View all Mycophenolic acid side effects |
||||||||||||||||
Drug Class | ||||||||||||||||||
Generic Availability | ||||||||||||||||||
N/A |
Lower cost generic |
|||||||||||||||||
Pricing and Coupons * Prices are without insurance | ||||||||||||||||||
We could not find an exact match for this medicine. Try searching the Price Guide directly. |
View all Myfortic prices |
View all Mycophenolic acid prices |
||||||||||||||||
Dosage Forms | ||||||||||||||||||
N/A |
|
|
||||||||||||||||
Brand Names | ||||||||||||||||||
N/A |
N/A |
Myfortic | ||||||||||||||||
Half Life Drug half-life is the time required for plasma concentration to reduce to half its original value. | ||||||||||||||||||
18 hours |
16 hours |
16 hours |
||||||||||||||||
CSA Schedule 1 View glossary of CSA terms | ||||||||||||||||||
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||||||||||
Pregnancy Category | ||||||||||||||||||
Category C
Risk cannot be ruled out
See the full pregnancy warnings document. |
Category D
Positive evidence of risk
See the full pregnancy warnings document. |
Category D
Positive evidence of risk
See the full pregnancy warnings document. |
||||||||||||||||
Drug Interactions | ||||||||||||||||||
A total of 180 drugs are known to interact with Orthoclone OKT3:
|
A total of 344 drugs are known to interact with Myfortic:
|
A total of 344 drugs are known to interact with Mycophenolic acid:
|
||||||||||||||||
Alcohol/Food/Lifestyle Interactions | ||||||||||||||||||
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
|
|
||||||||||||||||
Disease Interactions | ||||||||||||||||||
First Approval Date | ||||||||||||||||||
N/A |
February 27, 2004 |
February 27, 2004 |
||||||||||||||||
WADA Class View classifications | ||||||||||||||||||
N/A |
N/A |
N/A |
||||||||||||||||
More Information | ||||||||||||||||||
Patient Resources | ||||||||||||||||||
Professional Resources | ||||||||||||||||||
Related Treatment Guide | ||||||||||||||||||
1 The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
See also:
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.